Fredun Pharma

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE194R01017
  • NSEID: FREDUN
  • BSEID: 539730
INR
1,693.30
-14.4 (-0.84%)
BSENSE

Nov 20

BSE+NSE Vol: 10.42 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Fredun Pharma
Shukra Pharma.
Sakar Healthcare
Unichem Labs.
Solara Active
Ind-Swift Labs.
Hikal
Indoco Remedies
Advanced Enzyme
Sai Parenteral's
Panacea Biotec
Why is Fredun Pharmaceuticals Ltd ?
1
Healthy long term growth as Net Sales has grown by an annual rate of 35.86% and Operating profit at 65.71%
2
With a growth in Net Profit of 96.92%, the company declared Outstanding results in Sep 26
  • The company has declared positive results for the last 10 consecutive quarters
  • OPERATING CF(Y) Highest at Rs 16.44 Cr
  • ROCE(HY) Highest at 20.50%
  • NET SALES(Q) Highest at Rs 267.63 cr
3
Stock is technically in a Bullish range
  • The technical trend has improved from Mildly Bullish on 19-Nov-26
  • Multiple factors for the stock are Bullish like MACD, Bollinger Band, KST and DOW
4
Market Beating performance in long term as well as near term
  • Along with generating 161.15% returns in the last 1 year, the stock has outperformed BSE500 in the last 3 years, 1 year and 3 months
stock-recommendationReal-Time Research Report
Verdict Report
How much should you buy?
  1. Overall Portfolio exposure to Fredun Pharma should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Fredun Pharma for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Fredun Pharma
161.15%
1.84
87.77%
Sensex
-2.0%
-0.13
14.98%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
35.86%
EBIT Growth (5y)
65.71%
EBIT to Interest (avg)
2.65
Debt to EBITDA (avg)
2.74
Net Debt to Equity (avg)
0.73
Sales to Capital Employed (avg)
1.60
Tax Ratio
29.58%
Dividend Payout Ratio
1.15%
Pledged Shares
0
Institutional Holding
4.13%
ROCE (avg)
16.52%
ROE (avg)
14.49%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
54
Industry P/E
40
Price to Book Value
8.69
EV to EBIT
26.34
EV to EBITDA
23.85
EV to Capital Employed
5.45
EV to Sales
3.59
PEG Ratio
1.01
Dividend Yield
0.01%
ROCE (Latest)
20.68%
ROE (Latest)
16.16%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Bullish
Bullish
OBV
No Trend
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

42What is working for the Company
OPERATING CF(Y)

Highest at Rs 16.44 Cr

ROCE(HY)

Highest at 20.50%

NET SALES(Q)

Highest at Rs 267.63 cr

OPERATING PROFIT TO INTEREST(Q)

Highest at 4.82 times

PBDIT(Q)

Highest at Rs 42.35 cr.

PAT(Q)

Highest at Rs 18.57 cr.

DEBT-EQUITY RATIO(HY)

Lowest at 0.74 times

DEBTORS TURNOVER RATIO(HY)

Highest at 8.90 times

PBT LESS OI(Q)

Highest at Rs 29.65 cr.

-4What is not working for the Company
INTEREST(9M)

At Rs 31.89 cr has Grown at 28.54%

Loading Valuation Snapshot...
Here's what is working for Fredun Pharma
Net Sales - Quarterly
At Rs 267.63 cr has Grown at 84.19%
Year on Year (YoY)
MOJO Watch
Near term sales trend is very positive

Net Sales (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 29.65 cr has Grown at 133.28%
Year on Year (YoY)
MOJO Watch
Near term PBT trend is very positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 18.57 cr has Grown at 96.9%
Year on Year (YoY)
MOJO Watch
Near term PAT trend is very positive

PAT (Rs Cr)

Net Sales - Quarterly
Highest at Rs 267.63 cr and Grown
each quarter in the last five quarters
MOJO Watch
Near term sales trend is very positive

Net Sales (Rs Cr)

Operating Profit to Interest - Quarterly
Highest at 4.82 times
in the last five quarters
MOJO Watch
The company's ability to manage interest payments is improving

Operating Profit to Interest

Operating Profit (PBDIT) - Quarterly
Highest at Rs 42.35 cr. and Grown
each quarter in the last five quarters
MOJO Watch
Near term Operating Profit trend is quite positive

Operating Profit (Rs Cr)

Profit After Tax (PAT) - Quarterly
Highest at Rs 18.57 cr. and Grown
each quarter in the last five quarters
MOJO Watch
Near term PAT trend is very positive

PAT (Rs Cr)

Operating Cash Flow - Annually
Highest at Rs 16.44 Cr
in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 29.65 cr.
in the last five quarters
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Debt-Equity Ratio - Half Yearly
Lowest at 0.74 times
in the last five half yearly periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Debtors Turnover Ratio- Half Yearly
Highest at 8.90 times
in the last five half yearly periods
MOJO Watch
Company has been able to settle its Debtors faster

Debtors Turnover Ratio

Here's what is not working for Fredun Pharma
Interest - Nine Monthly
At Rs 31.89 cr has Grown at 28.54%
over preceding nine months period
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (Rs cr)